AR051325A1 - Analogos de biarilquinolin-4-ilamina sustituidos - Google Patents

Analogos de biarilquinolin-4-ilamina sustituidos

Info

Publication number
AR051325A1
AR051325A1 ARP050104253A ARP050104253A AR051325A1 AR 051325 A1 AR051325 A1 AR 051325A1 AR P050104253 A ARP050104253 A AR P050104253A AR P050104253 A ARP050104253 A AR P050104253A AR 051325 A1 AR051325 A1 AR 051325A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
independently selected
hydrogen
membered
Prior art date
Application number
ARP050104253A
Other languages
English (en)
Original Assignee
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp filed Critical Neurogen Corp
Publication of AR051325A1 publication Critical patent/AR051325A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proveen análogos de biarilquinolin-4-ilamina sustituidos de la formula (1). Dichos compuestos son ligandos que se pueden usar para modular la actividad específica de receptor in vivo o in vitro, y son particularmente utiles en el tratamiento de condiciones asociadas con la activacion patologica de receptor en humanos, animales domésticos de companía y animales de ganado. Se proveen composiciones farmacéutica y métodos para usar dichos compuestos para el tratamiento de dichos trastornos, al igual que métodos para usar dichos ligandos para estudios de localizacion de receptor. Reivindicacion 1: Un compuesto de la formula (1), o una de sus sales farmacéuticamente aceptables, donde: Y y Z son, de modo independiente, N o CR1; cada R1 es, de modo independiente, hidrogeno, halogeno, ciano, amino, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, haloalcoxi C1-4 o mono- o di-(alquilC1-4)amino; R2 es: i) hidrogeno, halogeno o ciano; ii) un grupo de la formula: -Rc-M-Rd-Ry, donde: Rc es alquileno C0-3 o está unido a Ry o Rz para formar un carbociclo o heterociclo de 4 a 10 miembros que está sustituida con 0 a 2 sustituyentes seleccionados, de modo independiente, de Rb; M está ausente, es un enlace covalente simple, O, S, SO, SO2, C(=O), OC(=O), C(=O)O, O-C(=O)O, C(=O)N(Rz), OC(=O)N(Rz), N(Rz)C(=O), N(Rz)C(=O)O, N(Rz)SO2, SO2N(Rz) o N(Rz), de modo que M no es N(Rz)C(=O)O cuando Rc es un enlace covalente simple; Rd está ausente, es un enlace covalente simple o alquileno C1-8 sustituido con 0 a 3 sustituyentes seleccionados, de modo independiente, de Rb; y Ry y Rz, de estar presentes, son: a) de modo independiente, hidrogeno, alquilo C1-8, alquilC2-8-éter, alquenilo C2-8, un carbociclo o heterociclo de 4 a 10 miembros, o están unidos a Rc para formar un carbociclo o heterociclo de 4 a 10 miembros, donde cada Ry y Rz no hidrogeno está sustituido con 0 a 6 sustituyentes seleccionados, de modo independiente, de Rb; o b) están unidos para formar un carbociclo o heterociclo de 4 a 10 miembros que está sustituido con 0 a 6 sustituyentes seleccionados, de modo independiente, de Rb; de modo que, cuando Y y Z son ambos N, entonces R2 no es NH2; o iii) se toman juntos con R7 para formar un anillo condensado de 5 a 7 miembros que está sustituido con 0 a 3 sustituyentes seleccionados, de modo independiente, de oxo y alquilo C1-4; R7 es hidrogeno, halogeno, COOH, alquilo C1-4, haloalquilo C1-4, alcoxi C1-4, alcoxicarbonilo C1-4 o se toma junto con R2 para formar un anillo condensado, opcionalmente sustituido; Ar1 es fenilo o heteroarilo de 6 miembros, cada uno de los cuales: i) está sustituido en un átomo de carbono del anillo en posicion meta o para respecto del punto de union con un sustituyente seleccionado de halogeno, ciano, nitro y grupos de la formula LRa; y ii) está sustituidos en cualquier/cualquiera otro/s átomo/s de carbono del anillo con 1-3 sustituyentes adicionales seleccionados, de modo independiente, de halogeno, ciano, nitro y grupos de la formula LRa; Ar2 es arilo de 6 a 10 miembros o heteroarilo de 5 a 10 miembros, cada uno de los cuales está sustituido con 0 a 6 sustituyentes seleccionados, de modo independiente, de oxo y grupos de la formula LRa; L está seleccionado en cada aparicion, de modo independiente, de un enlace covalente simple, O, C(=O), OC(=O), C(=O)O, OC(=O)O, S(O)m, N(Rx), C(=O)N(Rx), N(Rx)C(=O), N(Rx)S(O)m, S(O)mN(Rx) y N[S(O)mRw]S(O)m; donde m está seleccionado en cada aparicion, de modo independiente, de 0, 1 y 2; Rx está seleccionado en cada aparicion, de modo independiente, de hidrogeno, alquilo C1-6, alcanoilo C1-6 y alquilsulfonilo C1-6; y Rw es alquilo C1-6; Ra está seleccionado en cada aparicion, de modo independiente, de: i) hidrogeno, de modo que Ra no es hidrogeno cuando L es un enlace; y ii) alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilC3-8alquiloC0-6, haloalquilo C1-8, alquilC2-8-éter, mono- y di-(alquilC1-8)amino y heterociclo de 3 a 10 miembros alquilo C0-6, cada uno de los cuales está sustituido con 0 a 6 sustituyentes seleccionados, de modo independiente, de Rb; y Rb está seleccionado en cada aparicion, de modo independiente, de hidroxi, halogeno, amino, aminocarbonilo, aminosulfonilo, ciano, nitro, oxo, COOH, alquilo C1-8, alquenilo C1-8, alquinilo C1-8, alcoxi C1-8, alquiltio C1-8, alcanoilo C1-8, alcanoiloxi C2-8, alcoxicarbonilo C1-8, alquilC1-8-éter, hidroxialquilo C1-8, haloalquilo C1-8, mono- o di-(alquil C1-6)aminoalquiloC0-4, alquilsulfonilo C1-8, mono- o di-(alquil C1-6)aminocarbonilo, mono- o di-(alquil C1-6)aminosulfonilo, carbociclo de 3 a 7 miembros alquilo C0-8 y heterociclo de 4 a 7 miembros alquilo C0-8.
ARP050104253A 2004-10-12 2005-10-11 Analogos de biarilquinolin-4-ilamina sustituidos AR051325A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61848104P 2004-10-12 2004-10-12
US64169205P 2005-01-05 2005-01-05

Publications (1)

Publication Number Publication Date
AR051325A1 true AR051325A1 (es) 2007-01-03

Family

ID=36149023

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104253A AR051325A1 (es) 2004-10-12 2005-10-11 Analogos de biarilquinolin-4-ilamina sustituidos

Country Status (8)

Country Link
US (1) US7935702B2 (es)
EP (1) EP1811845A4 (es)
JP (1) JP2008515988A (es)
AR (1) AR051325A1 (es)
AU (1) AU2005295091A1 (es)
CA (1) CA2584081A1 (es)
TW (1) TW200621251A (es)
WO (1) WO2006042289A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432275B2 (en) * 2002-12-13 2008-10-07 Neurogen Corporation Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
DE10323345A1 (de) 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
ES2285525T3 (es) * 2003-07-10 2007-11-16 Neurogen Corporation Analogos de benzo(b)isotiazol-3-ilamina sustituidos con arilo como moduladores de los receptores de capsaicina.
TW200510373A (en) * 2003-07-14 2005-03-16 Neurogen Corp Substituted quinolin-4-ylamine analogues
WO2006081388A2 (en) * 2005-01-25 2006-08-03 Neurogen Corporation Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues
US20080153845A1 (en) * 2006-10-27 2008-06-26 Redpoint Bio Corporation Trpv1 antagonists and uses thereof
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8546388B2 (en) * 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
EP2352725A1 (en) * 2008-11-07 2011-08-10 Wyeth LLC Quinoxaline-based lxr modulators
EP3590925B1 (en) 2010-09-17 2022-03-30 Purdue Pharma L.P. Pyridine compounds and the uses thereof
AU2012224979B2 (en) 2011-03-09 2017-01-19 Merck Patent Gmbh Pyrido [2, 3 - b] pyrazine derivatives and their therapeutical uses
WO2023232917A1 (en) * 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Novel compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928281D0 (en) 1989-12-14 1990-02-21 Smith Kline French Lab Compounds
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
CN1230185A (zh) 1996-07-13 1999-09-29 葛兰素集团有限公司 双环芳杂环化合物用作蛋白质酪氨酸激酶的抑制剂
WO1998002434A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US5863016A (en) 1997-02-28 1999-01-26 The Wiremold Company Modular faceplate assembly having concealed latching means
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
DK2253620T3 (da) 1998-09-29 2014-03-31 Wyeth Holdings Llc Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
TW200406390A (en) 2002-01-17 2004-05-01 Neurogen Corp Substituted quinazolin-4-ylamine analogues
US7718651B2 (en) * 2002-07-02 2010-05-18 Southern Research Institute Inhibitors of FtsZ and uses thereof
WO2004054582A1 (en) 2002-12-13 2004-07-01 Neurogen Corporation Combination therapy for the treatment of pain
US7432275B2 (en) 2002-12-13 2008-10-07 Neurogen Corporation Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
TW200510373A (en) * 2003-07-14 2005-03-16 Neurogen Corp Substituted quinolin-4-ylamine analogues
AU2004270740A1 (en) 2003-09-09 2005-03-17 Neurogen Corporation 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists
JP2007532570A (ja) 2004-04-08 2007-11-15 ニューロジェン・コーポレーション 置換シンノリン−４−イルアミン類
WO2006081388A2 (en) 2005-01-25 2006-08-03 Neurogen Corporation Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues

Also Published As

Publication number Publication date
EP1811845A2 (en) 2007-08-01
AU2005295091A1 (en) 2006-04-20
CA2584081A1 (en) 2006-04-20
JP2008515988A (ja) 2008-05-15
WO2006042289A2 (en) 2006-04-20
TW200621251A (en) 2006-07-01
EP1811845A4 (en) 2009-07-15
WO2006042289A3 (en) 2006-06-22
US7935702B2 (en) 2011-05-03
US20060111337A1 (en) 2006-05-25

Similar Documents

Publication Publication Date Title
AR051325A1 (es) Analogos de biarilquinolin-4-ilamina sustituidos
AR053712A1 (es) Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
AR056892A1 (es) Derivados de cinolin-3-carboxamida, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion del receptor gabaa
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
AR050194A1 (es) Analogos de biaril piperazinil-piridina sustituidos
AR025386A1 (es) Moduladores de los receptores activados del proliferador de peroxisomas
UY25873A1 (es) Derivados de 3-azabiciclo [3.1.0] hexano útiles en terapia en afecciones mediadas por receptores opiáceos
AR065280A1 (es) Agentes antiparasitarios
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
AR078536A1 (es) Derivados de pirazol como ligandos del receptor de estrogeno
AR046244A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos
AR063022A1 (es) Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados.
AR044519A1 (es) Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR065499A1 (es) Inhibidores de serino proteasas.composiciones farmaceuticas
AR056560A1 (es) Pirrolopiridinonas como moduladores cb1
CO5690551A2 (es) Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo
AR053774A1 (es) Derivados de sulfonilbencimidazol. composiciones farmaceuticas.
ES2308299T3 (es) Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas.
AR040333A1 (es) Uso de derivados de ciclotiocarbamatos en el tratamiento de condiciones relacionadas con hormonas
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
AR045255A1 (es) Derivados de 1,2 benzodiazol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal